Wetenschappelijke publicaties van Bordet

Enhanced head and neck radiotherapy target definition through multidisciplinary delineation and peer review: A prospective single-center study.
Auteurs Dragan T, Soussy K, Beauvois S, Lefebvre Y, Lemort M, Ozalp E, Gulyban A, Burghelea M, Wardi CA, Marin C, Benkhaled S, Van Gestel D
Auteurs (entité) VAN GESTEL DIRK
Revue Clin Transl Radiat Oncol
Date de publication 2024-09

Enhanced head and neck radiotherapy target definition through multidisciplinary delineation and peer review: A prospective single-center study.

Enhanced head and neck radiotherapy target definition through multidisciplinary delineation and peer review: A prospective single-center study.
Auteurs Dragan T, Soussy K, Beauvois S, Lefebvre Y, Lemort M, Ozalp E, Gulyban A, Burghelea M, Wardi CA, Marin C, Benkhaled S, Van Gestel D
Auteurs (entité) DRAGAN TATIANA
Revue Clin Transl Radiat Oncol
Date de publication 2024-09

Enhanced head and neck radiotherapy target definition through multidisciplinary delineation and peer review: A prospective single-center study.

Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update.
Auteurs Loibl S, Jassem J, Sonnenblick A, Parlier D, Winer E, Bergh J, Gelber RD, Restuccia E, Im YH, Huang CS, Dalenc F, Calvo I, Procter M, Caballero C, Clark E, Raimbault A, McConnell R, Monturus E, de Azambuja E, Gomez HL, Bliss J, Viale G, Bines J, Piccart M
Auteurs (entité) DE AZAMBUJA EVANDRO
Revue J Clin Oncol
Date de publication 2024-09

Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update.

Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update.
Auteurs Loibl S, Jassem J, Sonnenblick A, Parlier D, Winer E, Bergh J, Gelber RD, Restuccia E, Im YH, Huang CS, Dalenc F, Calvo I, Procter M, Caballero C, Clark E, Raimbault A, McConnell R, Monturus E, de Azambuja E, Gomez HL, Bliss J, Viale G, Bines J, Piccart M
Auteurs (entité) PICCART MARTINE
Revue J Clin Oncol
Date de publication 2024-09

Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update.

Active surveillance for low-risk prostate cancer with high tumor burden at biopsy: lessons learned from a contemporary radical prostatectomy cohort.
Auteurs Oliva J, Anastay V, Baboudjian M, Roumiguié M, Peltier A, Dariane C, Fiard G, Roumeguère T, Diamand R, Bakhri M, Beauval JB, Long-Depaquit T, Ploussard G, Uleri A
Auteurs (entité) PELTIER ALEXANDRE
Revue World J Urol
Date de publication 2024-09

Active surveillance for low-risk prostate cancer with high tumor burden at biopsy: lessons learned from a contemporary radical prostatectomy cohort.

Active surveillance for low-risk prostate cancer with high tumor burden at biopsy: lessons learned from a contemporary radical prostatectomy cohort.
Auteurs Oliva J, Anastay V, Baboudjian M, Roumiguié M, Peltier A, Dariane C, Fiard G, Roumeguère T, Diamand R, Bakhri M, Beauval JB, Long-Depaquit T, Ploussard G, Uleri A
Auteurs (entité) DIAMAND ROMAIN
Revue World J Urol
Date de publication 2024-09

Active surveillance for low-risk prostate cancer with high tumor burden at biopsy: lessons learned from a contemporary radical prostatectomy cohort.

Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study.
Auteurs Jhaveri KL, Lim E, Jeselsohn R, Ma CX, Hamilton EP, Osborne C, Bhave M, Kaufman PA, Beck JT, Manso Sanchez L, Parajuli R, Wang HC, Tao JJ, Im SA, Harnden K, Yonemori K, Dhakal A, Neven P, Aftimos P, Yves-Pierga J, Lu YS, Larson T, Jerez Y, Sideras K, Sohn J, Kim SB, Saura C, Bardia A, Sammons SL, Bacchion F, Li Y, Yuen E, Estrem ST, Rodrik-Outmezguine V, Nguyen B, Ismail-Khan R, Smyth L, Beeram M
Auteurs (entité) AFTIMOS PHILIPPE
Revue J Clin Oncol
Date de publication 2024-09

Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study.

In Vitro Modulation of Human Foam Cell Formation and Adhesion Molecules Expression by Ginger Extracts Points to Potential Cardiovascular Preventive Agents.
Auteurs Scalia A, Coquay M, Kindt N, Duez P, Aro R, Journé F, Fabjanczyk M, Trelcat A, Carlier S
Auteurs (entité) KINDT NADEGE
Revue Int J Mol Sci
Date de publication 2024-08

In Vitro Modulation of Human Foam Cell Formation and Adhesion Molecules Expression by Ginger Extracts Points to Potential Cardiovascular Preventive Agents.

Characteristics and clinical outcomes of breast cancer in young BRCA carriers according to tumor histology.
Auteurs Agostinetto E, Bruzzone M, Hamy AS, Kim HJ, Chiodi C, Bernstein-Molho R, Linn S, Pogoda K, Carrasco E, Derouane F, Bajpai J, Nader-Marta G, Lopetegui-Lia N, Partridge AH, Cortesi L, Rousset-Jablonski C, Giugliano F, Renaud T, Ferrari A, Paluch-Shimon S, Fruscio R, Cui W, Wong SM, Vernieri C, Ruddy KJ, Dieci MV, Matikas A, Rozenblit M, Aguilar Y Mendez D, De Marchis L, Borea R, Puglisi F, Pistelli M, Kufel-Grabowska J, Di Rocco R, Mariamidze E, Atzori F, Kourie HR, Popovic L, de Azambuja E, Blondeaux E, Lambertini M
Auteurs (entité) AGOSTINETTO ELISA
Revue ESMO Open
Date de publication 2024-09

Characteristics and clinical outcomes of breast cancer in young BRCA carriers according to tumor histology.

Erasmusziekenhuis

Bekijk alle wetenschappelijke publicaties van Erasmus

Wetenschappelijke publicaties van Erasmus

Queen Fabiola Kinderziekenhuis

Bekijk alle wetenschappelijke publicaties van het Koningin Fabiola Kinderziekenhuis

Wetenschappelijke publicaties van het Koningin Fabiola-Kinderziekenhuis

Jules Bordet-instituut

Bekijk alle wetenschappelijke publicaties van Jules Bordet

Wetenschappelijke publicaties van Jules Bordet

Wetenschappelijke publicaties van Bordet

Wetenschappelijke publicaties van Bordet

Enhanced head and neck radiotherapy target definition through multidisciplinary delineation and peer review: A prospective single-center study.

Enhanced head and neck radiotherapy target definition through multidisciplinary delineation and peer review: A prospective single-center study.

Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update.

Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update.

Active surveillance for low-risk prostate cancer with high tumor burden at biopsy: lessons learned from a contemporary radical prostatectomy cohort.

Active surveillance for low-risk prostate cancer with high tumor burden at biopsy: lessons learned from a contemporary radical prostatectomy cohort.

Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study.

In Vitro Modulation of Human Foam Cell Formation and Adhesion Molecules Expression by Ginger Extracts Points to Potential Cardiovascular Preventive Agents.

Characteristics and clinical outcomes of breast cancer in young BRCA carriers according to tumor histology.

Erasmusziekenhuis

Queen Fabiola Kinderziekenhuis

Jules Bordet-instituut

Search for a keyword

Please select a hospital